FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912528055> ?p ?o ?g. }

• W2912528055 endingPage "798" @default.
• W2912528055 startingPage "788" @default.
• W2912528055 abstract "Practice patterns for the management of urinary retention (UR) secondary to benign prostatic obstruction (BPO; UR/BPO) vary widely and remain unstandardized. To review the evidence for managing patients with UR/BPO with pharmacological and nonpharmacological treatments included in the European Association of Urology guidelines on non-neurogenic male lower urinary tract symptoms. Search was conducted up to April 22, 2018, using CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform. This systematic review included randomized controlled trials (RCTs) and prospective comparative studies. Methods as detailed in the Cochrane handbook were followed. Certainty of evidence (CoE) was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Literature search identified 2074 citations. Twenty-one studies were included (qualitative synthesis). The evidence for managing patients with UR/BPO with pharmacological or nonpharmacological treatments is limited. CoE for most outcomes was low/very low. Only α1-blockers (alfuzosin and tamsulosin) have been evaluated in more than one RCT. Pooled results indicated that α1-blockers provided significantly higher rates of successful trial without catheter compared with placebo [alfuzosin: 322/540 (60%) vs 156/400 (39%) (odds ratio {OR} 2.28, 95% confidence interval {CI} 1.55 to 3.36; participants = 940; studies = 7; I2 = 41%; low CoE); tamsulosin: 75/158 (47%) vs 40/139 (29%) (OR 2.40, 95% CI 1.29 to 4.45; participants = 297; studies = 3; I2 = 30%; low CoE)] with rare adverse events. Similar rates were achieved with tamsulosin or alfuzosin [51/87 (59%) vs 45/84 (54%) (OR 1.28, 95% CI 0.68 to 2.41; participants = 171; studies = 2; I2 = 0%; very low CoE)]. Nonpharmacological treatments have been evaluated in RCTs/prospective comparative studies only sporadically. There is some evidence that usage of α1-blockers (alfuzosin and tamsulosin) may improve resolution of UR/BPO. As most nonpharmacological treatments have not been evaluated in patients with UR/BPO, the evidence is inconclusive about their benefits and harms. There is some evidence that alfuzosin and tamsulosin may increase the rates of successful trial without catheter, but little or no evidence on various nonpharmacological treatment options for managing patients with urinary retention secondary to benign prostatic obstruction." @default.
• W2912528055 created "2019-02-21" @default.
• W2912528055 creator A5010409135 @default.
• W2912528055 creator A5012198646 @default.
• W2912528055 creator A5012539089 @default.
• W2912528055 creator A5017093341 @default.
• W2912528055 creator A5020683373 @default.
• W2912528055 creator A5023386699 @default.
• W2912528055 creator A5027594088 @default.
• W2912528055 creator A5033540200 @default.
• W2912528055 creator A5034935464 @default.
• W2912528055 creator A5044096483 @default.
• W2912528055 creator A5057978449 @default.
• W2912528055 creator A5068797509 @default.
• W2912528055 creator A5073103100 @default.
• W2912528055 creator A5077678731 @default.
• W2912528055 creator A5088364554 @default.
• W2912528055 date "2019-05-01" @default.
• W2912528055 modified "2023-10-15" @default.
• W2912528055 title "Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis" @default.
• W2912528055 cites W1493056280 @default.
• W2912528055 cites W1537881186 @default.
• W2912528055 cites W1555820031 @default.
• W2912528055 cites W1875486484 @default.
• W2912528055 cites W1926796983 @default.
• W2912528055 cites W1966597157 @default.
• W2912528055 cites W1967312126 @default.
• W2912528055 cites W1968860914 @default.
• W2912528055 cites W1968993922 @default.
• W2912528055 cites W1976751461 @default.
• W2912528055 cites W1979547541 @default.
• W2912528055 cites W1993924540 @default.
• W2912528055 cites W2014760033 @default.
• W2912528055 cites W2017721657 @default.
• W2912528055 cites W2019044761 @default.
• W2912528055 cites W2027089019 @default.
• W2912528055 cites W2027189010 @default.
• W2912528055 cites W2028168119 @default.
• W2912528055 cites W2030698665 @default.
• W2912528055 cites W2059664549 @default.
• W2912528055 cites W2072028505 @default.
• W2912528055 cites W2073867668 @default.
• W2912528055 cites W2077640879 @default.
• W2912528055 cites W2081597080 @default.
• W2912528055 cites W2081713574 @default.
• W2912528055 cites W2086243966 @default.
• W2912528055 cites W2089348302 @default.
• W2912528055 cites W2093043874 @default.
• W2912528055 cites W2096998881 @default.
• W2912528055 cites W2103743099 @default.
• W2912528055 cites W2125435699 @default.
• W2912528055 cites W2133124362 @default.
• W2912528055 cites W2135400982 @default.
• W2912528055 cites W2137012067 @default.
• W2912528055 cites W2160033699 @default.
• W2912528055 cites W2170212612 @default.
• W2912528055 cites W2396434716 @default.
• W2912528055 cites W2508609181 @default.
• W2912528055 cites W2755459284 @default.
• W2912528055 cites W2891302405 @default.
• W2912528055 cites W3022903699 @default.
• W2912528055 cites W3152223563 @default.
• W2912528055 cites W4294215472 @default.
• W2912528055 doi "https://doi.org/10.1016/j.eururo.2019.01.046" @default.
• W2912528055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30773327" @default.
• W2912528055 hasPublicationYear "2019" @default.
• W2912528055 type Work @default.
• W2912528055 sameAs 2912528055 @default.
• W2912528055 citedByCount "45" @default.
• W2912528055 countsByYear W29125280552019 @default.
• W2912528055 countsByYear W29125280552020 @default.
• W2912528055 countsByYear W29125280552021 @default.
• W2912528055 countsByYear W29125280552022 @default.
• W2912528055 countsByYear W29125280552023 @default.
• W2912528055 crossrefType "journal-article" @default.
• W2912528055 hasAuthorship W2912528055A5010409135 @default.
• W2912528055 hasAuthorship W2912528055A5012198646 @default.
• W2912528055 hasAuthorship W2912528055A5012539089 @default.
• W2912528055 hasAuthorship W2912528055A5017093341 @default.
• W2912528055 hasAuthorship W2912528055A5020683373 @default.
• W2912528055 hasAuthorship W2912528055A5023386699 @default.
• W2912528055 hasAuthorship W2912528055A5027594088 @default.
• W2912528055 hasAuthorship W2912528055A5033540200 @default.
• W2912528055 hasAuthorship W2912528055A5034935464 @default.
• W2912528055 hasAuthorship W2912528055A5044096483 @default.
• W2912528055 hasAuthorship W2912528055A5057978449 @default.
• W2912528055 hasAuthorship W2912528055A5068797509 @default.
• W2912528055 hasAuthorship W2912528055A5073103100 @default.
• W2912528055 hasAuthorship W2912528055A5077678731 @default.
• W2912528055 hasAuthorship W2912528055A5088364554 @default.
• W2912528055 hasBestOaLocation W29125280553 @default.
• W2912528055 hasConcept C121608353 @default.
• W2912528055 hasConcept C126322002 @default.
• W2912528055 hasConcept C126894567 @default.
• W2912528055 hasConcept C142724271 @default.
• W2912528055 hasConcept C156957248 @default.
• W2912528055 hasConcept C168563851 @default.
• W2912528055 hasConcept C17744445 @default.

• next